Heng Fai Ambrose Chan
Chief Executive Officer at Alset Inc.
Sits on 4 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 11 years
- Director since
- 2023
11 years of board service in total across 4 boards, counting each seat separately. Longest: Alset Inc., 3 years.
Chief executive roles
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 3, 2026 | DSS Inc. | Open-market sale | −21,852 | $0.82 | $17,919 |
| Aug 7, 2026 | EnerSyn Global Inc. | Grant or award | +1,480,000 | — | — |
| Aug 5, 2026 | EnerSyn Global Inc. | Other | +320,000 | — | — |
| Jun 8, 2026 | EnerSyn Global Inc. | Open-market purchase | +250,000 | $2.00 | $500,000 |
| Mar 30, 2026 | EnerSyn Global Inc. | Open-market sale | −100,390 | $0.98 | $98,382 |
| Nov 26, 2025 | EnerSyn Global Inc. | Grant or award | +1,000,000 | — | — |
| Sep 12, 2025 | Alset Inc. | Open-market sale | −500,000 | $2.67 | $1,335,000 |
| Aug 28, 2025 | DSS Inc. | Open-market sale | +130,679 | $1.35 | $176,417 |
| Aug 18, 2025 | Alset Inc. | Open-market purchase | +33,000 | $1.29 | $42,570 |
| Jul 23, 2025 | Alset Inc. | Other | +27,666,667 | — | — |
| Jun 30, 2025 | Alset Inc. | Grant or award | +280,000 | — | — |
| Apr 15, 2025 | Alset Inc. | Grant or award | +1,000,000 | — | — |
| Apr 4, 2025 | Impact BioMedical Inc. | Open-market sale | −180,000 | $0.96 | $172,800 |
| Apr 3, 2025 | Impact BioMedical Inc. | Open-market sale | −351,555 | $0.50 | $175,778 |
| Apr 3, 2025 | Impact BioMedical Inc. | Open-market sale | −351,631 | $0.58 | $203,946 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.